Doing science the Wonga way

The model used by the payday loans company might finally make science work for everyone. Could we be about to enter the age of Wonga science?

Occasionally a corporate entity tries to get science done its way. Google, for instance, sponsors various researchers to find out whether their worthy, planet-improving idea can work. But what would we get if the payday loans company Wonga.com sponsored science?

It’s not an idle question. Just recently, up in committee room 17 of the House of Commons, Chi Onwurah, Labour’s science minister, gathered academics and asked for thoughts on the public role of science and how we should fund it. The responses weren’t terribly conclusive or enlightening. But one interesting thing came up – the origins of Wonga.

Wonga’s eye-watering prices (borrowing £400 for 28 days will cost you £117.48, for example) have been the subject of questions downstairs in the Commons and the Lords. Stella Creasy MP is trying to get the Financial Services Authority to cap the rate of interest a company can charge. She is supported in the other chamber by the future archbishop of Canterbury, who has called Wonga’s business model “morally wrong”.

Apparently the algorithm behind Wonga.com was originally developed to detect banking fraud. The subtext in Onwurah’s meeting was clear – Wonga is an evil application of perfectly good algorithms, and if someone had said those algorithms could lead to Wonga questions would have been asked of those funding their development. Especially, perhaps, if Onwurah were in charge. When Wonga ploughed £24m into Newcastle Football Club in exchange for on-shirt advertising, Onwurah, MP for Newcastle Central, expressed outrage. She called Wonga a source of “debt and misery”.

There are two reasons to take issue with this. First, many people are clearly happy to pay hundreds of pounds for a short-term loan. Wonga’s reported customer satisfaction is above Apple’s and far above that recorded by any of the high-street banks. Second, Onwurah’s remit is innovation, science and digital infrastructure and yet she slurs a company that has used science and digital infrastructure to innovate. The firm is expanding into the US and is on course to become a billion-dollar company next year.

The good news is that the government will soon have a Wonga-friendly chief scientific adviser. Mark Walport is at present the director of the Wellcome Trust, the UK’s largest scientific and medical research charity and an investor in Wonga. When Creasy challenged Walport about this, he replied that he finds Wonga “extremely engaging”, with a good business model and a willingness to listen to feedback.

This bodes extremely well for Walport’s stint as the UK’s most influential scientist. Clearly, he’s not populist, he’s not swayed by conflicts with authority and he’s not averse to a bit of level-headed thinking.

Coming round

If Onwurah comes round, she and Walport might even usher in the age of Wonga science. This would be open to no-fuss funding of projects and people that are currently considered unfundable, ending the pyramid scheme that makes life easy for established professors and near-impossible for those trying to become established. It would reward people who cross disciplines to achieve optimum productivity (one of Wonga’s co-founders, Jonty Hurwitz, trained as a mathematician and physicist and then became a software engineer and entrepreneur). Pursuing interdisciplinary research is widely known as a fast track to the funding wilderness.

Wonga science would present straight-talking science advice to government and pursue research that has no useful application in sight. It would also encourage scientists to take things we already have and find entirely new purposes for them. Most appealing, it might show us gaps in our scientific research that no one even realised were there. The Wonga model might finally make science work for everyone.

 

Michael Brooks holds a PhD in quantum physics. He writes a weekly science column for the New Statesman, and his most recent book is At the Edge of Uncertainty: 11 Discoveries Taking Science by Surprise.

This article first appeared in the 17 December 2012 issue of the New Statesman, Will Europe ever go to war again?

Getty Images/ Staff
Show Hide image

The answer to the antibiotics crisis might be inside your nose

The medical weapons we have equipped ourselves with are losing their power. But scientists scent an answer. 

They say there’s a hero in everyone. It turns out that actually, it resides within only about ten percent of us. Staphylococcus lugdunensis may be the species of bacteria that we arguably don’t deserve, but it is the one that we need.

Recently, experts have cautioned that we may be on the cusp of a post-antibiotic era. In fact, less than a month ago, the US Centres for Disease Control and Prevention released a report on a woman who died from a "pan-resistant" disease – one that survived the use of all available antibiotics. Back in 1945, the discoverer of penicillin, Alexander Fleming, warned during his Nobel Prize acceptance speech against the misuse of antibiotics. More recently, Britain's Chief Medical Officer Professor Dame Sally Davies has referred to anti-microbial resistance as “the greatest future threat to our civilisation”.

However, hope has appeared in the form of "lugdunin", a compound secreted by a species of bacteria found in a rather unlikely location – the human nose.

Governments and health campaigners alike may be assisted by a discovery by researchers at the University of Tubingen in Germany. According to a study published in Nature, the researchers had been studying Staphylococcus aureus. This is the bacteria which is responsible for so-called "superbug": MRSA. A strain of MRSA bacteria is not particularly virulent, but crucially, it is not susceptible to common antibiotics. This means that MRSA spreads quickly from crowded locations where residents have weaker immune systems, such as hospitals, before becoming endemic in the wider local community. In the UK, MRSA is a factor in hundreds of deaths a year. 

The researchers in question were investigating why S. aureus is not present in the noses of some people. They discovered that another bacteria, S. lugdunensis, was especially effective at wiping out its opposition, even MRSA. The researchers named the compound created and released by the S. lugdunensis "lugdunin".

In the animal testing stage, the researchers observed that the presence of lugdunin was successful in radically reducing and sometimes purging the infection. The researchers subsequently collected nasal swabs from 187 hospital patients, and found S. aureus on roughly a third of the swabs, and S. lugdunensis on up to 10 per cent of them. In accordance with previous results, samples that contained both species saw an 80 per cent decrease of the S. aureus population, in comparison to those without lugdunin.

Most notably, the in vitro (laboratory) testing phase provided evidence that the new discovery is also useful in eliminating other kinds of superbugs, none of which seemed to develop resistance to the new compound. The authors of the study hypothesised that lugdunin had evolved  “for the purpose of bacterial elimination in the human organism, implying that it is optimised for efficacy and tolerance at its physiological site of action". How it works, though, is not fully understood. 

The discovery of lugdunin as a potential new treatment is a breakthrough on its own. But that is not the end of the story. It holds implications for “a new concept of finding antibiotics”, according to Andreas Peschel, one of the bacteriologists behind the discovery.

The development of antibiotics has drastically slowed in recent years. In the last 50 years, only two new classes of this category of medication have been released to the market. This is due to the fact almost all antibiotics in use are derived from soil bacteria. By contrast, the new findings record the first occurrence of a strain of bacteria that exists within human bodies. Some researchers now suggest that the more hostile the environment to bacterial growth, the more likely it may be for novel antibiotics to be found. This could open up a new list of potential areas in which antibiotic research may be carried out.

When it comes to beating MRSA, there is hope that lugdunin will be our next great weapon. Peschel and his fellow collaborators are in talks with various companies about developing a medical treatment that uses lugdunin.

Meanwhile, in September 2016, the United Nations committed itself to opposing the spread of antibiotic resistance. Of the many points to which the UN signatories have agreed, possibly the most significant is their commitment to “encourage innovative ways to develop new antibiotics”. 

The initiative has the scope to achieve a lot, or dissolve into box ticking exercise. The discovery of lugdunin may well be the spark that drives it forward. Nothing to sniff about that. 

Anjuli R. K. Shere is a 2016/17 Wellcome Scholar and science intern at the New Statesman